Table 1.
Clinical characteristics of 64 patients with difficult-to-treat Crohn’s disease, at baseline.
| Characteristic | Value |
|---|---|
| Age, years, mean (SD) | 64.2 (9.8) |
| Age disease at diagnosis, years, mean (SD) | 22.4 (9.8) |
| Disease duration, years, mean (SD) | 14.5 (9.2) |
| Female, n (%) | 25 (39.1) |
| Current smokers, n (%) | 10 (15.6) |
| Previous abdominal surgery, n (%) | 43 (67.2) |
| Extra-intestinal manifestations, n (%) | 28 (43.8) |
| Disease location, n (%) | |
| Ileal | 10 (15.6) |
| Colonic | 16 (25.0) |
| Ileocolonic | 38 (59.4) |
| Upper disease, n (%) | 11 (17.2) |
| Perianal disease, n (%) | 29 (45.3) |
| Current use of corticosteroids, n (%) | 29 (45.3) |
| Behavior, n (%) | |
| Inflammatory | 26 (40.6) |
| Stricturing | 21 (32.8) |
| Fistulizing | 17 (25.6) |
| Clinical disease activity, n (%) | |
| Mild (HBIc 5–7) | 5 (7.9) |
| Moderate (HBIc 8–16) | 46 (73.0) |
| Severe (HBIc > 16) | 12 (19.0) |
| Endoscopic disease activity, n (%) | |
| Mild (SES-CDd < 6) | 0 (0.0) |
| Moderate (SES-CDd 6–15) | 36 (56.2) |
| Severe (SES-CDd > 15) | 28 (43.8) |
| C-reactive protein > 0.5 mg/dL, n (%) | 38 (59.4)a |
| Fecal calprotectin > 250 μg/g feces, n (%) | 50 (86.2)b |
| Fecal calprotectin > 150 μg/g feces, n (%) | 58 (100)b |
aData missing for 1 patient.
bData missing for 6 patients.
cHBI, Harvey-Bradshaw index.
dSES-CD, simple endoscopic score for Crohn’s disease.